Posters

      Using an iTRAQ Approach to Investigate the Effect of Cigarette Smoke Exposure in a 90-day Inhalation Study Followed by 42-days Recovery Period on Sprague-Dawley Rats Lung Tissues

      Elamin, A.; Schneider, T.; Dijon, S.; Wong, E. T.; Titz, B.; Martin, F.; Kogel, U.; Vanscheeuwijck, P.; Ivanov, N. V.; Hoeng, J.; Peitsch, M. C.
      Conference date
      Oct 5, 2014
      Conference name

      13th HUPO (Human Proteome Organization) Annual World Congress
      Link to more information
      Topic
      Summary

      In order to update and advance our knowledge regarding the impact of cigarette smoke on the lungs of Sprague-Dawley rats, a system biology approach that combines state-of-the-art proteomics with transcriptomics and toxicological endpoints, was developed. A 90-day inhalation study followed by recovery period of 42 days was conducted as described in the Organization for Economic Co-operation and Development (OECD) Testing Guideline 413. A quantitative proteomics approach using isobaric tags for absolute and relative quantification (iTRAQ®) was performed on the lung tissues of Sprague-Dawley rats to detect changes in protein expression levels between control rats (exposed to air), and rats exposed to mainstream smoke (MS) of the Reference Cigarette 3R4F (2 exposure concentrations of 8, and 23 mg/L nicotine). For the recovery period, the same treatment and control groups were used. Six biological replicates were analyzed to assess reproducibility within each group. The obtained mass-spectrometry data was searched against the Uniprot rat reference proteome database. Exposure of Sprague-Dawley rats to MS induced inflammatory changes in the lungs as detected by an increase in number of differentially expressed proteins and networks perturbed (as determined by network enrichment approaches) compared to the control sample. At the end of the recovery period, the protein expression profiles of MS-exposed rats showed a decreased amount of differentially expressed proteins indicating reverting back to normal levels compared to the control rats; that was shown by monitoring at least10 of the highly regulated proteins. The obtained proteomics results complemented those obtained from other endpoints such as transcriptomics, lipidomics as well as lung histopathology, thereby providing a unique opportunity to reveal underlying molecular mechanisms of MS exposure that were captured within this study that will further establish the foundation of PMI’s systems biology approach to assess the impact of modified risk tobacco products (MRTPs) on biological systems.

      Related Publications

      A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

      Pre-clinical Toxicology

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.